CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-03). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 2103 · Search date 2026-08-03 · Methodology v0.6

Breakfast skipping,
does it really help with Weight gain or impaired weight loss over 16 weeks?

30-Second Summary
D
Evidence Grade D · 34 · Safety acceptable
Advice to skip breakfast did not increase weight over 16 weeks
No major safety signal was reported from breakfast advice in generally healthy adults with overweight. People using glucose-lowering medication should separately consider hypoglycemia and medication timing.
What the
research shows
The grade is D with 34 points. In 309 randomized adults with overweight or obesity, the 16-week intention-to-treat analysis using multiple imputation found no effect of advice to eat or skip breakfast on weight change. The 283-completer analysis also found no assignment effect (P=0.77). Calories were not matched, so this tests practical advice including compensatory intake, but it does not support the claim that skipping breakfast causes weight gain.
What the
ads claim
An observational association between breakfast skipping and obesity does not prove causation. Direct assignment did not produce weight gain over 16 weeks.
*

Useful facts when choosing a product

  • Breakfast participants ate before 10 am; skipping participants consumed no calories before 11 am, with later intake uncontrolled.
  • The primary analysis included all 309 randomized participants; 283 completed.
  • Verdict 1647 is D with 34 points for extra weight loss from an unrestricted-calorie eight-hour window; this verdict tests breakfast advice and 16-week weight change.
Gap Measurement · Verdict 2103 · D 34
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Dhurandhar et al. randomized 309 adults across five sites: 105 control, 101 advised to eat breakfast before 10 am, and 103 advised to consume no calories before 11 am. Allocation used sequentially numbered opaque sealed envelopes. The primary weight outcome was measured on an electronic scale, while self-report diaries were used only for secondary outcomes. A total of 283 completed; 8.4% missing weight-change data were multiply imputed for the 309-person primary analysis. Adjusted completer changes were roughly -0.53 to -0.76 kg across strata, with assignment P=0.77 and similar imputed results. Treating the unavoidable absence of participant blinding alone as a defect would automatically penalize every dietary-behavior trial. NIH-related grants and the Nordea Foundation supported this study. Separately, authors and institutions disclosed gifts, grants, or consulting relationships with Kraft, Kellogg, Quaker/Pepsi, the Dairy Research Institute, the Egg Board, McDonald's, General Mills, Nutrisystem, Dunkin' Donuts, Post Cereals, and others; these were not funding for this study.

02

Why this is classified as D (34)

A relatively large publicly supported randomized trial found a null registered primary weight outcome, but no precise treatment CI was verified, giving D with 34 points.

Counterpoint. This verdict does not address breakfast quality or separate glycemic outcomes.

Rejudgment record. Cross-check applied — Null registered primary weight endpoint in a 309-participant intention-to-treat randomized trial, without a verified treatment confidence interval

Scoring profile behind this grade
EndpointPPatient-reported treatment goal - the symptom is the goal
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE0Null
PrecisionCXNo pooled confidence interval could be confirmed

The scoring table and the verdict agree (D).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Sixteen-week weight gain from breakfast skippingDNo assignment effect was found in all 309 randomized participants.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Multisite three-arm randomized effectiveness trial283This study was supported by NIH-related grants and the Nordea Foundation; separate food-industry gifts, grants, and consulting relationships were disclosedRegistered primary endpoint of 16-week weight changeNo assignment effect; completer P=0.77 with similar multiple-imputation ITT resultsRelatively large direct null trial
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-03).

Dhurandhar EJ, Dawson J, Alcorn A, et al. The effectiveness of breakfast recommendations on weight loss: a randomized controlled trial. Am J Clin Nutr. 2014;100(2):507-513. PMID: 24898236. DOI: 10.3945/ajcn.114.089573.
checked
ClinicalTrials.gov. NCT01781780. Randomized Controlled Trial of Breakfast Recommendations on Weight.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-03 · Corrections: none

Cite this verdict

Breakfast skipping x 16-week weight gain Evidence Grade D card
[Chamgap] Breakfast skipping x 16-week weight gain — Evidence Grade D·34. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/breakfast-skipping-sixteen-week-weight-gain/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.